Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Centessa Pharmaceuticals ( (CNTA) ) is now available.
On November 11, 2025, Centessa Pharmaceuticals announced an underwriting agreement to issue and sell 11,627,907 American Depositary Shares (ADSs) at $21.50 per share, with an option for underwriters to purchase an additional 1,744,186 ADSs. The offering is expected to close on November 14, 2025, and aims to raise approximately $234.4 million, potentially increasing to $269.6 million if the over-allotment option is exercised. The proceeds will fund the development of product candidates and general corporate purposes, potentially supporting operations until 2028. This move is part of Centessa’s strategy to bolster its financial resources for ongoing and future projects, thereby strengthening its position in the pharmaceutical industry.
The most recent analyst rating on (CNTA) stock is a Buy with a $35.00 price target. To see the full list of analyst forecasts on Centessa Pharmaceuticals stock, see the CNTA Stock Forecast page.
Spark’s Take on CNTA Stock
According to Spark, TipRanks’ AI Analyst, CNTA is a Underperform.
Centessa Pharmaceuticals has a low overall stock score due to significant financial challenges, including ongoing losses, negative cash flow, and a bearish technical outlook. The lack of profitability reflected in the negative P/E ratio further contributes to the low score. Investors should be cautious, considering the company’s need for additional funding to sustain operations in the capital-intensive biotechnology industry.
To see Spark’s full report on CNTA stock, click here.
More about Centessa Pharmaceuticals
Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company focused on discovering and developing transformational medicines. The company is pioneering therapies within its orexin receptor 2 (OX2R) agonist program, targeting symptoms such as excessive daytime sleepiness, impaired attention, cognitive deficits, and fatigue across neurological, neurodegenerative, and neuropsychiatric disorders.
Average Trading Volume: 1,400,546
Technical Sentiment Signal: Buy
Current Market Cap: $3.59B
For detailed information about CNTA stock, go to TipRanks’ Stock Analysis page.